Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
NCT04957160
·
clinicaltrials.gov ↗
COMPLETED
Status
281
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Renal Cell Carcinoma (aRCC)
Sponsor
Ipsen